Overview Financials News + Filings Key Docs Charts Transactions Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Asset disposition
Quarterly results
Acq. announced
CC transcript
Employment agrmnt
Coll. bargaining agrmnt
Director departure
|
|
NOVELION THERAPEUTICS INC. (NVLNF)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 07/14/2020 |
8-K
| Quarterly results |
| 06/12/2020 |
8-K
| Other Events, Financial Statements and Exhibits Interactive Data |
| 01/21/2020 |
8-K
| Bankruptcy or Receivership, Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officer...|
Docs:
|
"Novelion Therapeutics Confirms Commencement of Voluntary Liquidation VANCOUVER, British Columbia, January 16, 2020 – Novelion Therapeutics Inc. today announced that the implementation of the Company’ s voluntary liquidation commenced at 5:00 p.m. Pacific Time today, January 16, 2020 . As of the Effective Date, Alvarez & Marsal Canada Inc. was appointed liquidator and charged with overseeing all aspects of the Liquidation. Concurrent with the Liquidator’ s appointment: Michael Price, previously Executive Vice President, Chief Financial Officer and sole executive officer and employee of the Company, resigned his positions, and Michael Price, Suzanne Bruhn, and Stephen Sabba resigned as directors of the Company. Shareholders and other interested parties should visit www.alvarezandmarsal.com/n..." |
|
| 01/03/2020 |
8-K
| Quarterly results |
| 12/11/2019 |
8-K
| Regulation FD Disclosure, Financial Statements and Exhibits Interactive Data |
| 11/05/2019 |
8-K
| Submission of Matters to a Vote of Security Holders, Other Events |
| 10/08/2019 |
8-K
| Quarterly results |
| 10/03/2019 |
8-K
| Quarterly results |
| 09/27/2019 |
8-K
| Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Departure of Directors o... |
| 09/25/2019 |
8-K
| Bankruptcy or Receivership, Completion of Acquisition or Disposition of Assets, Departure of Directors or Certain Officers; E... |
| 09/11/2019 |
8-K
| Quarterly results |
| 08/30/2019 |
8-K
| Other Events |
| 08/21/2019 |
8-K
| Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Other Events |
| 07/17/2019 |
8-K
| Other Events |
| 07/15/2019 |
8-K
| Bankruptcy or Receivership, Financial Statements and Exhibits |
| 07/05/2019 |
8-K
| Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing |
| 07/01/2019 |
8-K
| Bankruptcy or Receivership, Financial Statements and Exhibits |
| 06/24/2019 |
8-K
| Quarterly results |
| 05/21/2019 |
8-K
| Entry into a Material Definitive Agreement, Bankruptcy or Receivership, Triggering Events That Accelerate or Increase a Direc...|
Docs:
|
"Restructuring Support Agreement, by and among, the Company, the Debtors, the Plan Investor, and the Consenting Creditors",
"Plan Funding Agreement, by and among, Aegerion and the Plan Investor",
"Amendment to the Shared Services Agreements, by and among the Company, Novelion Services USA, Inc. and Aegerion",
"Novelion Therapeutics Announces Subsidiary Aegerion Pharmaceuticals to Recapitalize Through Court Supervised Process In Which Amryt Pharma Plc Will Acquire 100% of Reorganized Stock of Aegerion",
"Additional Materials (furnished)" |
|
| 05/07/2019 |
8-K
| Quarterly results|
Docs:
|
"Novelion Therapeutics Reports First Quarter 2019 Financial Results – Company reiterates 2019 guidance of total net revenues between $160.0 and $175.0 million, including approximately $30.0 million of licensing revenues VANCOUVER, British Columbia, and CAMBRIDGE, MA, May 7, 2019 - Novelion Therapeutics Inc. , a biopharmaceutical company dedicated to developing and commercializing therapies for individuals living with rare diseases , today reported financial results for the first quarter ended March 31, 2019. Novelion’s Interim Chief Executive Officer Ben Harshbarger commented, “We continue to execute on our goals of achieving target revenues, maximizing the impact of the operating cost reductions that we implemented in late 2018, working with the FDA on the development program for the poten..." |
|
| 03/14/2019 |
8-K
| Quarterly results|
Docs:
|
"Novelion Therapeutics Reports Fourth Quarter and Full Year 2018 Financial Results – Company achieves FY 2018 total net revenues of $130.4 million – FY 2018 operating expenses reduced by $27.2 million, or 18.4% VANCOUVER, British Columbia, and Cambridge, MA, March 14, 2019 - Novelion Therapeutics Inc. , a biopharmaceutical company dedicated to developing and commercializing therapies for individuals living with rare diseases , today reported financial results for the fourth quarter and year ended December 31, 2018. Novelion’s Interim Chief Executive Officer Ben Harshbarger commented, “We are pleased with our fourth quarter results which reflect strong revenue performance and show meaningful impact from the cost reduction initiatives executed throughout 2018. We remain focused on undertaking..." |
|
| 02/06/2019 |
8-K
| Quarterly results |
| 02/04/2019 |
8-K
| Quarterly results |
| 11/26/2018 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 11/20/2018 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 11/09/2018 |
8-K
| Quarterly results |
| 11/08/2018 |
8-K
| Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance S... |
| 09/25/2018 |
8-K
| Resignation/termination of a director |
| 09/20/2018 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 09/17/2018 |
8-K
| Resignation/termination of a director |
| 08/23/2018 |
8-K
| Cost Associated with Exit or Disposal Activities, Regulation FD Disclosure, Financial Statements and Exhibits |
| 08/13/2018 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 08/07/2018 |
8-K
| Quarterly results|
Docs:
|
"Novelion Therapeutics Reports Second Quarter 2018 Financial Results Following recent marketing approval in both generalized and partial lipodystrophy indications, European launch of MYALEPTA® has commenced VANCOUVER, British Columbia, August 7, 2018 - Novelion Therapeutics Inc. , a biopharmaceutical company dedicated to developing and commercializing therapies for individuals living with rare diseases , today reported financial results for the second quarter and six months ended June 30, 2018 and provided an overview of business activities. Interim Chief Executive Officer Jeff Hackman commented, “Under our new leadership team, we are laser focused on maximizing the potential of our two commercial assets, enhancing our operational efficiencies by reducing costs, and fixing our capital struc..." |
|
| 07/19/2018 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
|
|
|